-
1Academic Journal
-
2Academic Journal
Συγγραφείς: Maria I. Kaleda, Irina P. Nikishina, Alesya V. Firsa, М. И. Каледа, И. П. Никишина, А. В. Фирса
Συνεισφορές: The manuscript was prepared within the fundamental research topic (research within the state assignment) No. 1021051302580-4 at the Research Institute of Rheumatology named after V.A. Nasonova. The authors express gratitude to the employees of the National Medical Research Center of Endocrinology — deputy head physician, candidate of medicine, G.N. Svetlova, head of pediatric department of diabetes mellitus, doctor of medicine, D.N. Laptev, and diagnostic radiology department of Research Institute of Rheumatology named after V.A. Nasonova., Подготовка рукописи выполнена в рамках фундаментальной научной темы (исследования, выполняемого в рамках государственного задания) № 1021051302580-4 в НИИ ревматологии им. В.А. Насоновой. Авторы выражают благодарность за помощь в обследовании и лечении пациентки сотрудникам Национального медицинского исследовательского центра эндокринологии — заместителю главного врача к.м.н. Г.Н. Светловой, заведующему детским отделением сахарного диабета д.м.н. Д.Н. Лаптеву, сотрудникам отделения лучевой диагностики НИИ ревматологии им. В.А. Насоновой.
Πηγή: Current Pediatrics; Том 22, № 6 (2023); 546-553 ; Вопросы современной педиатрии; Том 22, № 6 (2023); 546-553 ; 1682-5535 ; 1682-5527
Θεματικοί όροι: белимумаб, oral glucocorticoids, steroid-induced diabetes, avascular necrosis, belimumab, пероральные глюкокортикоиды, стероидный диабет, аваскулярный некроз
Περιγραφή αρχείου: application/pdf
Relation: https://vsp.spr-journal.ru/jour/article/view/3356/1350; das Chagas Medeiros MM, Bezerra MC, Braga FN, et al. Clinical and immunological aspects and outcome of a Brazilian cohort of 414 patients with systemic lupus erythematosus (SLE): comparison between childhood-onset, adult-onset, and late-onset SLE. Lupus. 2016;25(4):355–363. doi: https://doi.org/10.1177/0961203315606983; Асеева Е.А., Лила А.М., Соловьев С.К. и др. Клинико-иммунологические фенотипы системной красной волчанки, выделенные на основании кластерного анализа данных 400 пациентов ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой» // Современная ревматология. — 2022. — Т. 16. — № 5. — С. 13–21. — doi: https://doi.org/10.14412/1996-7012-2022-5-13-21; Hoffman IE, Lauwerys BR, De Keyser F, et al. Juvenile-onset systemic lupus erythematosus: different clinical and serological pattern than adult-onset systemic lupus erythematosus. Ann Rheum Dis. 2009;68(3):412–415. doi: https://doi.org/10.1136/ard.2008.094813; Guzman M, Hui-Yuen JS. Management of Pediatric Systemic Lupus Erythematosus: Focus on Belimumab. Drug Des Devel Ther. 2020;14:2503–2513. doi: https://doi.org/10.2147/DDDT.S216193; Hedrich CM, Smith EMD, Beresford MW. Juvenile-onset systemic lupus erythematosus (jSLE) — Pathophysiological concepts and treatment options. Best Pract Res Clin Rheumatol. 2017;31(4):488–504. doi: https://doi.org/10.1016/j.berh.2018.02.001; Насонов Е.Л., Попкова Т.В., Лила А.М. Белимумаб в лечении системной красной волчанки: 20 лет фундаментальных исследований, 10 лет клинической практики // Научно-практическая ревматология. — 2021. — Т. 59. — № 4. — С. 367–383. — doi: https://doi.org/10.47360/1995-4484-2021-367-383; Watson L, Beresford MW, Maynes C, et al. The indications, efficacy and adverse events of rituximab in a large cohort of patients with juvenile-onset SLE. Lupus. 2015;24(1):10–17. doi: https://doi.org/10.1177/0961203314547793; Trindade VC, Carneiro-Sampaio M, Bonfa E, Silva CA. An Update on the Management of Childhood-Onset Systemic Lupus Erythematosus. Paediatr Drugs. 2021;23(4):331–347. doi: https://doi.org/10.1007/s40272-021-00457-z; Каледа М.И., Никишина И.П., Николаева Е.В. и др. Ритуксимаб при ревматических заболеваниях у детей: результаты ретроспективного исследования безопасности терапии // Научно-практическая ревматология. — 2021. — Т. 59. — № 2. — С. 208– 214. — doi: https://doi.org/10.47360/1995-4484-2021-208-214; Chen F, Zheng Y, Chen X, et al. Belimumab in childhood systemic lupus erythematosus: A review of available data. Front Immunol. 2022; 13:940416. doi: https://doi.org/10.3389/fimmu.2022.940416; Brunner HI, Abud-Mendoza C, Viola DO, et al. Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG). Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial. Ann Rheum Dis. 2020;79(10):1340–1348. doi: https://doi.org/10.1136/annrheumdis-2020-217101; Fontana F, Alfano G, Leonelli M, et al. Efficacy of Belimumab for active lupus nephritis in a young Hispanic woman intolerant to standard treatment: a case report. BMC Nephrol. 2018;19(1):276. doi: https://doi.org/10.1186/s12882-018-1066-3; Zeng HQ, Lu XP, Yan ZB, Ye ZZ. First case presentation of refractory pediatric bullous lupus erythematosus (BSLE) treatment with belimumab. Eur Rev Med Pharmacol Sci. 2022;26(21):7980– 7985. doi: https://doi.org/10.26355/eurrev_202211_30151; Wang D, Shan C, Liu J, et al. Efficacy and safety of belimumab for the treatment of refractory childhood-onset systemic lupus erythematosus: A single-center, real-world, retrospective study. Front Immunol. 2022;13:1067721. doi: https://doi.org/10.3389/fimmu.2022.1067721; Suh S, Park MK. Glucocorticoid-Induced Diabetes Mellitus: An Important but Overlooked Problem. Endocrinol Metab (Seoul). 2017;32(2):180–189. doi: https://doi.org/10.3803/EnM.2017.32.2.180; Bao S, Huang H, Jin Y, et al. Autoantibody-based subgroups and longitudinal seroconversion in juvenile-onset systemic lupus erythematosus. Lupus Sci Med. 2023;10(1):e000834. doi: https://doi.org/10.1136/lupus-2022-000834; Gladman DD, Urowitz MB, Goldsmith CH, et al. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum. 1997;40(5):809–813. doi: https://doi.org/10.1002/art.1780400506; Rella V, Rotondo C, Altomare A, et al. Bone Involvement in Systemic Lupus Erythematosus. Int J Mol Sci. 2022;23(10):5804. doi: https://doi.org/10.3390/ijms23105804; Yang Y, Kumar S, Lim LS, et al. Risk Factors for Symptomatic Avascular Necrosis in Childhood-onset Systemic Lupus Erythematosus. J Rheumatol. 2015;42(12):2304–2349. doi: https://doi.org/10.3899/jrheum.150464; Groot N, de Graeff N, Avcin T, et al. European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: the SHARE initiative. Ann Rheum Dis. 2017;76(11):1788–1796. doi: https://doi.org/10.1136/annrheumdis-2016-210960; Алексеева Е.И., Дворяковская Т.М., Никишина И.П. и др. Системная красная волчанка: клинические рекомендации. Часть 2 // Вопросы современной педиатрии. — 2018. — Т. 17. — № 2. — С. 110–125. — doi: https://doi.org/10.15690/vsp.v17i2.1877; Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745. doi: https://doi.org/10.1136/annrheumdis-2019-215089; Hammam N, Evans M, Bell CF, et al. Evaluating the Use of Glucocorticoids Among Belimumab-Treated Patients With Systemic Lupus Erythematosus in Real-World Settings Using the Rheumatology Informatics System for Effectiveness Registry. ACR Open Rheumatol. 2022;4(10):883–889. doi: https://doi.org/10.1002/acr2.11482; Massias JS, Smith EM, Al-Abadi E, et al. Clinical and laboratory phenotypes in juvenile-onset Systemic Lupus Erythematosus across ethnicities in the UK. Lupus. 2021;30(4):597–607. doi: https://doi.org/10.1177/0961203320984251; Lim LSH, Pullenayegum E, Lim L, et al. From childhood to adulthood: the trajectory of damage in patients with juvenile-onset systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2017;69(11):1627–1635. doi: https://doi.org/10.1002/acr.23199; Malagón C, Gomez MDP, Mosquera C, et al. Juvenile polyauto-immunity in a rheumatology setting. Autoimmun Rev. 2019;18(4): 369–381. doi: https://doi.org/10.1016/j.autrev.2018.11.006; Setoue DN, Pitta AC, Fiorot FJ, et al. Brazilian Childhood-onset Systemic Lupus Erythematosus Group. Symptomatic polyautoimmunity at diagnosis of 1463 childhood-onset lupus: A Brazilian multicenter study. Autoimmun Rev. 2018;17(8): 836–839. doi: https://doi.org/10.1016/j.autrev.2018.03.009; Heshin-Bekenstein M, Trupin L, Yelin E, et al. Longitudinal disease- and steroid-related damage among adults with childhood-onset systemic lupus erythematosus. Semin Arthritis Rheum. 2019;49(2):267–272. doi: https://doi.org/10.1016/j.semarthrit.2019.05.010; Nakamura J, Saisu T, Yamashita K, et al. Age at time of corticosteroid administration is a risk factor for osteonecrosis in pediatric patients with systemic lupus erythematosus: a prospective magnetic resonance imaging study. Arthritis Rheum. 2010;62(2):609–615. doi: https://doi.org/10.1002/art.27236; Tsai HL, Chang JW, Lu JH, Liu CS. Epidemiology and risk factors for avascular necrosis in childhood systemic lupus erythematosus in a Taiwanese population. Sci Rep. 2020;10(1):15563. doi: https://doi.org/10.1038/s41598-020-71923-w; Kallas R, Li J, Petri M. Predictors of Osteonecrosis in Systemic Lupus Erythematosus: A Prospective Cohort Study. Arthritis Care Res (Hoboken). 2022;74(7):1122–1132. doi: https://doi.org/10.1002/acr.24541; Kunyakham W, Foocharoen C, Mahakkanukrauh A, et al. Prevalence and risk factor for symptomatic avascular necrosis development in Thai systemic lupus erythematosus patients. Asian Pac J Allergy Immunol. 2012;30(2):152–157.; Nevskaya T, Gamble MP, Pope JE. A meta-analysis of avascular necrosis in systemic lupus erythematosus: prevalence and risk factors. Clin Exp Rheumatol. 2017;35(4):700–710.; Sakamoto M, Shimizu K, Iida S, et al. Osteonecrosis of the femoral head: a prospective study with MRI. J Bone Joint Surg Br. 1997;79(2): 213–219. doi: https://doi.org/10.1302/0301-620x.79b2.7179; Gurion R, Tangpricha V, Yow E, et al. Atherosclerosis Prevention in Pediatric Lupus Erythematosus Investigators. Avascular necrosis in pediatric systemic lupus erythematosus: a brief report and review of the literature. Pediatr Rheumatol Online J. 2015;13:13. doi: https://doi.org/10.1186/s12969-015-0008-x36.; Hui-Yuen JS, Reddy A, Taylor J, et al. Safety and Efficacy of Belimumab to Treat Systemic Lupus Erythematosus in Academic Clinical Practices. J Rheumatol. 2015;42(12):2288–2295. doi: https://doi.org/10.3899/jrheum.150470